Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-05-17
2005-05-17
Badio, Barbara P. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
C552S653000
Reexamination Certificate
active
06894037
ABSTRACT:
This invention provides a novel vitamin D analog, namely, 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol. The compound has the formula:This 2-substituted compound is characterized by relatively high intestinal calcium transport activity and relatively low bone calcium mobilization activity resulting in novel therapeutic agents for the treatment of diseases where bone formation is desired, particularly osteoporosis. These compounds also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as anti-cancer agents and for the treatment of diseases such as psoriasis.
REFERENCES:
patent: 4666634 (1987-05-01), Miyamoto et al.
patent: 4800198 (1989-01-01), DeLuca et al.
patent: 5086191 (1992-02-01), DeLuca et al.
patent: 5089641 (1992-02-01), DeLuca et al.
patent: 5237110 (1993-08-01), DeLuca et al.
patent: 5246925 (1993-09-01), DeLuca et al.
patent: 5536713 (1996-07-01), DeLuca et al.
patent: 5578587 (1996-11-01), DeLuca et al.
patent: 5587497 (1996-12-01), DeLuca et al.
patent: 5817648 (1998-10-01), Kutner et al.
patent: 5843927 (1998-12-01), DeLuca
patent: 5843928 (1998-12-01), Deluca et al.
patent: 5846960 (1998-12-01), Labrie
patent: 5849726 (1998-12-01), Brenner
patent: 5877168 (1999-03-01), Miyamoto et al.
patent: 5936133 (1999-08-01), DeLuca et al.
patent: 5945410 (1999-08-01), DeLuca et al.
patent: 6114317 (2000-09-01), DeLuca et al.
patent: 6392071 (2002-05-01), DeLuca et al.
patent: 6696431 (2004-02-01), DeLuca et al.
patent: 0184206 (1985-12-01), None
patent: 0078704 (1987-04-01), None
patent: 0387077 (1990-09-01), None
patent: 0480572 (1992-04-01), None
patent: 0474517 (1992-11-01), None
patent: 0516410 (1992-12-01), None
patent: WO9009991 (1990-09-01), None
patent: WO9601811 (1996-01-01), None
Chemical Abstracts, XP-00206605, vol. 121, No. 21, Nov. 21, 1994.
Posner et al, “2-Fluoroalkyl A-Ring Analogs of 1,25-Dihydroxyvitamin D3-Stereocontrolled Total Synthesis via Intramolecular and Intermolecular Diels-Alder Cycloadditions. Preliminary Biological Testing”, Journal of Organic Chemistry, 60, pp. 4617-4628, 1995.
Slatopolsky et al, “A New Analog of Calcitriol, 19-Nor-1,25-(OH)2 D2 Supresses Parathyroid Hormone Secretion in Uremaic Rats in the Absence of Hypercalcemia”, American Journal of Kidney Disorders, 26(5), 832-60, 1995.
Posner et al, “Stereocontrolled Synthesis of a Trihydroxylated A Ring as an Immediate Precursor to 1Alpha,2Alpha,25-Trihydroxyvitamin D3”, Journal of Organic Chemistry, 56, pp. 4339-4341, Apr. 15, 1995.
Chemical Abstracts, “Chemistry of Synthetic High Polymers”, vol. 110, No. 10, Abstract 110: 82505v, Mar. 6, 1989.
Okano et al, “Regulatory Activities of 2Beta-(3-Hydroxypropoxy)-1Alpha,25-Dihydroxyvitamin D3. A Novel Synthetic Vitamin D3 Derivative on Calcium Metabolism”, Biochemical and Biophysical Research Communications, vol. 163, No. 3, pp. 1444-1449, Sep. 29, 1989.
Bouillon et al, “Biological Activity of Dihydroxylated 19-Nor-(Pre)Vitamin D3”, Bioactivity of 19-Nor-Pre D, vol. 8, No. 8, pp. 1009-1015, 1993.
Sarandeses et al, “Synthesis of 1Alpha,25-Dihydroxy-19-Norprevitamin D3”, tetrahedron Letters, pp. 5445-5448, Apr. 1992.
Perlman et al, “1Alpha,25-Dihydroxy-19-Nor-Vitamin D3, A Novel Vitamin D-Related Compound with Potential Therapeutic Activity”, Tetrahedron Letters, vol. 31, No. 13, pp. 1823-1824, Feb. 1990.
Baggiolini et al, “Stereochemical Total Synthesis of 1Alpha,25-Dihydroxycholecalciferol and 1Beta,25-Dihydroxyerocalciferol”, Journal of Organic Chemistry, 51, pp. 3098-3108, 1986.
Kiegiel et al, “Chemical Conversion of Vitamin D3 to its 1,25-Dihydroxy Metabolite”, Tetrahedron Letters, vol. 31, No. 43, pp. 6057-60660, 1991.
Sicinski et al, “New 1Alpha,25-Ihydroxy-19-Norvitamin D3 Compounds of High Biological Activity: Synthesis and Biological Evaluation of 2-Hydroxymethyl, 2-Methyl, and 2-Methylene Analogues”, Journal of Medical Chemistry, 41, pp. 4662-4674, 1998.
Brown et al, “New Active Analogues of Vitamin D with Low Calcemic Activity”, Kidney International, vol. 38, Suppl. 29, 1990, pp. S-22-S-27.
Hareau et al, “Asymmetric Synthesis of 1Alpha,25-Dihydroxyvitamin D3 A-Ring Precursor Starting with 5-Tert-Butyldimethylsiloxy-2-Cyclohexenone”, Tetrahedron Letters, 41, 2000, pp. 2385-2388.
DeLuca Hector F.
Grzywacz Pawel K.
Andrus, Sceales, Starke and Sawall, LLP
Badio Barbara P.
Wisconsin Alumni Research Foundation
LandOfFree
2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalcifero... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalcifero..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalcifero... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3439215